Deals
AstraZeneca Snubs Pfizer Approach That U.K. Won’t Block
This article is for subscribers only.
AstraZeneca Plc rejected Pfizer Inc.’s sweetened takeover proposal, saying the 62.6 billion-pound ($105.6 billion) offer fails to appreciate the value of the promising medicines under development by the U.K.’s second-biggest drugmaker.
The cash-and-stock offer, which values AstraZeneca at about 50 pounds a share based on today’s closing price for Pfizer, also still relies too heavily on equity, London-based AstraZeneca said in a statement. AstraZeneca earlier rejected a proposal of 46.61 pounds a share, announced April 28.